Bellevue Group AG Increases Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Bellevue Group AG raised its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 13.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,779 shares of the company’s stock after purchasing an additional 581 shares during the period. Bellevue Group AG’s holdings in Krystal Biotech were worth $870,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Jamison Private Wealth Management Inc. bought a new position in shares of Krystal Biotech during the 2nd quarter valued at about $28,000. Key Financial Inc purchased a new position in Krystal Biotech in the 2nd quarter worth $28,000. GAMMA Investing LLC lifted its stake in Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after purchasing an additional 93 shares during the last quarter. Blue Trust Inc. boosted its position in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after buying an additional 163 shares during the period. Finally, Values First Advisors Inc. purchased a new position in shares of Krystal Biotech in the third quarter worth about $53,000. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS opened at $197.42 on Monday. The firm has a market capitalization of $5.68 billion, a P/E ratio of 111.54 and a beta of 0.82. The stock has a 50 day moving average price of $180.49 and a 200-day moving average price of $183.89. Krystal Biotech, Inc. has a 52-week low of $100.78 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company’s revenue for the quarter was up 879.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.67) earnings per share. On average, equities analysts forecast that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This trade represents a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 14.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on KRYS. Evercore ISI increased their price objective on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research note on Monday, August 12th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. HC Wainwright restated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Tuesday, November 5th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Finally, Citigroup raised their target price on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Krystal Biotech has an average rating of “Buy” and a consensus target price of $202.29.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).